Go Pro

Abbott Laboratories (ABT) Stock Price, News & Analysis

Abbott Laboratories logo
$90.68 -2.03 (-2.19%)
Closing price 06/30/2026 04:00 PM Eastern
Extended Trading
$91.15 +0.47 (+0.52%)
As of 06/30/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Abbott Laboratories Stock (NYSE:ABT)

Advanced

Key Stats

Today's Range
$90.61
$93.29
50-Day Range
$82.58
$96.06
52-Week Range
$81.97
$137.49
Volume
9.61 million shs
Average Volume
13.70 million shs
Market Capitalization
$157.95 billion
P/E Ratio
25.40
Dividend Yield
2.78%
Price Target
$118.30
Consensus Rating
Moderate Buy

Company Overview

Abbott Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
100th Percentile Overall Score

ABT MarketRank™: 

Abbott Laboratories scored higher than 100% of companies evaluated by MarketBeat, and ranked 1st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 2 strong buy ratings, 19 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Abbott Laboratories has a consensus price target of $118.30, representing about 30.5% upside from its current price of $90.68.

  • Amount of Analyst Coverage

    Abbott Laboratories has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Abbott Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Abbott Laboratories are expected to grow by 10.40% in the coming year, from $5.48 to $6.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abbott Laboratories is 25.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 46.44.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abbott Laboratories is 25.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.51.

  • Price to Earnings Growth Ratio

    Abbott Laboratories has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Abbott Laboratories has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Abbott Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    1.27% of the float of Abbott Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Abbott Laboratories has a short interest ratio ("days to cover") of 1.77, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Abbott Laboratories has recently decreased by 0.32%, indicating that investor sentiment is improving.
  • Dividend Yield

    Abbott Laboratories pays a meaningful dividend of 2.72%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Abbott Laboratories has been increasing its dividend for 54 years.

  • Dividend Coverage

    The dividend payout ratio of Abbott Laboratories is 70.59%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.65% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

  • Read more about Abbott Laboratories' dividend.
  • News Sentiment

    Abbott Laboratories has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 46 news articles for Abbott Laboratories this week, compared to 12 articles on an average week.
  • Search Interest

    Only 88 people have searched for ABT on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
  • MarketBeat Follows

    33 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days.
  • Cluster Insider Buying

    2 insiders have purchased shares of Abbott Laboratories in the last three months. Multiple insiders buying is a strong bullish signal.

  • Insider Buying vs. Insider Selling

    In the past three months, Abbott Laboratories insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,127,800.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    0.46% of the stock of Abbott Laboratories is held by insiders.

  • Percentage Held by Institutions

    75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abbott Laboratories' insider trading history.
Receive ABT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Stock News Headlines

Wells Fargo Remains a Buy on Abbott Laboratories (ABT)
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
Sector Update: Healthcare Stocks Higher Late Afternoon
See More Headlines

ABT Stock Analysis - Frequently Asked Questions

Abbott Laboratories' stock was trading at $125.30 on January 1st, 2026. Since then, ABT stock has decreased by 27.6% and is now trading at $90.68.

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings data on Thursday, April, 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories's quarterly revenue was up 7.8% compared to the same quarter last year.
Read the conference call transcript
.

Abbott Laboratories subsidiaries include these companies: Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and more.

Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include JPMorgan Chase & Co. (JPM), Chevron (CVX), NVIDIA (NVDA), Predictive Oncology (POAI), Bank of America (BAC), Meta Platforms (META) and AbbVie (ABBV).

Company Calendar

Record date for 5/15 Dividend
4/15/2026
Ex-Dividend for 5/15 Dividend
4/15/2026
Last Earnings
4/16/2026
Dividend Payable
5/15/2026
Today
7/01/2026
Record date for 8/17 Dividend
7/15/2026
Ex-Dividend for 8/17 Dividend
7/15/2026
Next Earnings (Estimated)
7/16/2026
Dividend Payable
8/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Equipment
Current Symbol
NYSE:ABT
CIK
1800
Employees
115,000
Year Founded
1888

Price Target and Rating

High Price Target
$143.00
Low Price Target
$92.00
Potential Upside/Downside
+30.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
26 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.57
Trailing P/E Ratio
25.40
Forward P/E Ratio
16.55
P/E Growth
1.6
Net Income
$6.52 billion
Net Margins
13.90%
Pretax Margin
18.03%
Return on Equity
17.62%
Return on Assets
10.01%

Debt

Debt-to-Equity Ratio
0.56
Current Ratio
1.39
Quick Ratio
1.01

Sales & Book Value

Annual Sales
$44.33 billion
Price / Sales
3.56
Cash Flow
$6.84 per share
Price / Cash Flow
13.26
Book Value
$30.35 per share
Price / Book
2.99

Miscellaneous

Outstanding Shares
1,741,810,000
Free Float
1,733,801,000
Market Cap
$157.95 billion
Optionable
Optionable
Beta
0.63

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:ABT) was last updated on 7/1/2026 by MarketBeat.com Staff.
From Our Partners